SimpleTest by iAssay: Improving medical testing by putting the lab in the palm of your hand | Wefunder
⚕️For too long huge healthcare technology companies have created closed systems that prioritize profits over patient care. Fortunately, technology innovation, spurred by the Covid-19 pandemic has helped achieve a breakthrough that will upend this $82 Billion industry. iAssay has developed a patented Point of Care (POC) testing device, SimpleTest, that completely changes the game.🧪We’ve taken the lab, fixed it, and put it in your pocket
👩⚕️ What is Point of Care?
Something hurts, maybe you ignore it at first, but after a couple of days it hurts enough that you finally decide to go to the doctor who orders a couple of basic tests. Now you’ve got to make an appointment, go to a lab, get the tests done and wait for the results. Finally you have a follow up with the doctor. If you’re lucky the whole thing took a week, and that was before Covid. But, it doesn’t have to be that way; POC test readers enable many of the most common laboratory tests to be done anywhere, with results in minutes. Even better, POC readers automate manual processes, which means less human errors, less false positives and better patient outcomes
Meet what we believe to be the first and only universal POC testing device
The hallmark of a closed system is when everything is proprietary. test strips work on device and device only. Lonnie Adelman, iAssay's CEO had a better idea. He imagined a universal reader that allows hundreds of different tests from dozens of manufacturers all to be read on a single cloud-connected device. SimpleTest can analyze a wide array of tests including drugs of abuse, cardiology, hematology, OB/GYN, infectious diseases, oncology, and Covid-19.Their their their
💡 An idea is born
Lonnie Adelman is an engineer both by training and force of habit. An HP veteran, it was about 7 years ago that Lonnie first learned about point of care testing. He was dismayed that you couldn’t perform the range of tests a patient needed with a single device, because each reader was limited to the set of tests belonging to a particular manufacturer
🌳 After a year of tinkering Lonnie noticed that a commonality in the tests would allow for cross-platform reading. Then came a breakthrough. Smartphone technology had advanced to the point where it could be implemented into the reader! What was needed was an adapter, a modular system that would allow for interoperability. The addition of data syncing with multiple data cloud platforms was the final piece of the puzzle. The seeds of SimpleTest, a revolutionary, holistic solution, had taken root
💰 The Opportunity
The POC testing industry has experienced explosive growth in the past year, which is only for the foreseeable future. Added to this, SimpleTest’s HIPAA compliant ability to sync with multiple cloud computing platforms enables anonymized data for research and big data mining, itself to be a staggering $68 Billion industry by 2025. SimpleTest has a range of application settings from Medical clinics, nursing homes, long term care facilities to workplace drug and covid testing, to individuals. Healthcare data providers such as Advera, Optum and Apixio would be an independent revenue stream.projected to increase projected
🏆Competitor Landscape
🏁 Go To Market
SimpleTest is ready to go to market today. Current partnerships with GattaCo, Vanderbilt Medical, and David Geffen School of Medicine have validated our business model. On the horizon are potential partnerships with worldwide, national and regional labs
We’re ready to tear down the barriers that have hindered healthcare for too long
Now is the time to democratize medical testing, and transform data into treatment
Wefunder means Wefunder Inc and its wholly owned subsidiaries: Wefunder Advisors LLC and Wefunder Portal LLC. This page is hosted by Wefunder Portal LLC
Wefunder Portal LLC is a member of the . Wefunder is risky. Don’t invest more than you can afford to lose. Financial Industry Regulatory Authority (FINRA) Investing on